beta-carotene(VitA) / ROS Cancer Research Results

betaCar, beta-carotene(VitA): Click to Expand ⟱

Features:

beta-Carotene (Vitamin A precursor) — Beta-carotene is a lipophilic provitamin A carotenoid and dietary pigment that can be enzymatically converted to retinal/retinol and, downstream, retinoic acid–active metabolites. It is formally classified as a nutritional carotenoid / vitamin precursor rather than an approved anticancer drug. Standard abbreviations include β-carotene and BC. Major sources are carotenoid-rich plants such as carrots, sweet potatoes, pumpkin, leafy greens, and supplements. In cancer biology, its profile is context-dependent: it can show antiproliferative, pro-apoptotic, and redox-modulating effects in vitro, but oral supplementation has not translated into cancer prevention benefit in randomized trials and high-dose supplementation has shown harm in smokers and asbestos-exposed populations.

Primary mechanisms (ranked):

Retinoid precursor biology with downstream modulation of differentiation/gene-expression programs via retinoid signaling (indirect, context-dependent).
Redox modulation in lipid membranes, including antioxidant singlet-oxygen/peroxyl-radical quenching at physiologic conditions and pro-oxidant behavior under oxidative/high-oxygen stress.
Apoptosis and cell-cycle regulation in some cancer models, linked to ROS-sensitive mitochondrial signaling and suppression of survival pathways.
Downregulation of prosurvival/inflammatory signaling such as NF-κB, Akt, ERK, and COX-2 in selected in-vitro systems.
Context-dependent modulation of NRF2-linked antioxidant defenses, sometimes decreasing tumor-cell antioxidant buffering in responsive models.
Clinical translation constraint: variable intestinal absorption, dependence on dietary fat/micellarization, tissue-specific metabolism, and adverse trial outcomes in high-risk smoking populations.

Bioavailability / PK relevance: Oral absorption is variable and strongly food-matrix- and fat-dependent because β-carotene is highly lipophilic and must be released from the food matrix and incorporated into mixed micelles before uptake. Typical carotenoid absorption is limited, and conversion to retinoids is heterogeneous across individuals. Delivery systems can increase exposure, but standard oral exposure remains nutritionally relevant rather than reliably pharmacologic.

In-vitro vs systemic exposure relevance: Some anticancer cell findings occur at low micromolar concentrations that can overlap with high-end human plasma β-carotene ranges after supplementation, but many mechanistic and pro-oxidant observations are highly context-dependent and may require oxidative conditions, tissue stress, or local concentrations not reproduced in vivo. The strongest human signal is not efficacy but harm in smokers at supplement doses of 20–30 mg/day.

Clinical evidence status: Human evidence does not support β-carotene as an anticancer therapy or reliable chemopreventive agent. RCT evidence for premalignant lesions is negative or inconclusive, and major prevention trials showed no cancer-prevention benefit with increased lung-cancer risk in smokers / asbestos-exposed groups. Best categorized as preclinical / failed prevention translation with population-specific safety concern.

Beta carotene is a red-orange pigment found in plants and fruits, especially carrots and colorful vegetables. The body converts beta carotene into vitamin A.
-foods richest in carotenoids include carrots, sweet potatoes, pumpkin, spinach, cantaloupe, apricots and mangoes.
Beta carotene is a carotenoid and an antioxidant.
beta-carotene is known to have pro-oxidant activity in vitro
Beta carotene, a precursor of vitamin A and a well-known antioxidant, has been investigated for its potential roles in cancer prevention and therapy.

-By mitigating oxidative stress, beta carotene may indirectly reduce NF-κB activation.
-As a lipid-soluble molecule, beta carotene is integrated into cellular membranes, where it helps maintain membrane integrity and fluidity.
-at high concentrations or in the presence of high oxygen tension), beta carotene can exhibit pro-oxidant behavior, which may contribute to cellular damage.

Cancer Mechanistic relevance table

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Retinoid precursor signaling	↔ / differentiation↑ (context-dependent)	retinoid support↑	G	Gene-expression modulation	β-carotene is upstream of retinal/retinol biology, so any antitumor differentiation effect is indirect and depends on cleavage, tissue handling, and downstream retinoid signaling rather than direct receptor agonism.
2	Redox balance in lipid compartments	ROS↓ or ROS↑ (context-dependent)	oxidative injury↓	R	Membrane-phase redox modulation	Core duality of β-carotene: antioxidant under many physiologic conditions, but can become pro-oxidant under oxidative stress or high oxygen tension. This context dependence likely explains discordance between bench and trial outcomes.
3	Mitochondrial ROS increase	ROS↑, cytochrome c release↑, apoptosis↑	↔ / oxidative buffering↑	R	Apoptosis induction in responsive models	Reported in breast-cancer models, where β-carotene increased ROS, impaired mitochondrial function, and promoted caspase-linked death. This is not universal across tumor types.
4	Akt ERK NF-κB survival signaling	Akt↓, ERK↓, NF-κB↓	↔	G	Reduced survival signaling	Observed in selected in-vitro systems at low micromolar exposure. Supports antiproliferative interpretation, but clinical confirmation is lacking.
5	PPARγ p21 COX-2 axis	PPARγ↑, p21↑, COX-2↓	↔	G	Growth arrest and pro-differentiation stress response	One mechanistic branch links β-carotene to PPARγ-associated apoptosis and cell-cycle restraint, especially in MCF-7 models.
6	NRF2 antioxidant defense	NRF2↓ (model-dependent)	↔ / antioxidant support↑	G	Lower tumor antioxidant buffering	Not universal, but some cancer-cell data show suppression of NRF2-linked antioxidant enzymes, which may permit apoptosis in oxidatively stressed tumor cells.
7	Cell cycle and apoptosis machinery	Bcl-2↓, PARP↓, caspase activity↑, S-phase arrest↑ (model-dependent)	↔	G	Antiproliferative effect	Useful as a downstream summary row because multiple upstream axes converge on apoptosis and growth inhibition in vitro.
8	Chemosensitization	doxorubicin sensitivity↑ (model-dependent)	normal-cell toxicity ↔	G	Adjunct potential in preclinical models	Preclinical evidence suggests possible co-adjuvant activity in some breast-cancer models, but this remains non-clinical and should not override the adverse prevention-trial history.
9	Tobacco-smoke oxidative interaction	DNA oxidative damage↑, COX-2↑, apoptosis escape↑	injury↑	G	Potential harm under smoke-related oxidative stress	This is the most clinically important context. Under smoke-related oxidative conditions, β-carotene and/or its breakdown products may shift toward pro-carcinogenic behavior.
10	Clinical Translation Constraint	exposure heterogeneity↑	safety concern in smokers↑	G	Poor translation to oncology use	Variable absorption, dependence on fat/micelles, metabolism to retinoids or oxidative cleavage products, inconsistent tumor exposure, negative premalignancy RCTs, and increased lung-cancer risk in smokers make β-carotene unsuitable as a general anticancer intervention.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr

Alzheimer's disease relevance table

Rank	Pathway / Axis	Modulation	Primary Effect	Notes / Interpretation
1	Neuronal oxidative stress	ROS injury ↓	Neuroprotection	Most consistent AD-relevant rationale. β-carotene can quench lipid-phase oxidative stress and may help preserve neuronal integrity, although this is still context-dependent and not uniquely specific to AD.
2	Retinoid signaling support	RAR RXR signaling ↑ (indirect)	Synaptic plasticity and memory support	Because β-carotene is a provitamin A source, part of its relevance may come from supporting retinoic-acid-dependent transcriptional programs important in hippocampal function and learning.
3	Amyloid beta pathology	Aβ aggregation ↓ (preclinical)	Reduced amyloid burden	Preclinical and biophysical studies suggest β-carotene can alter Aβ aggregation behavior, and mouse-model work supports lower neuropathology, but this remains non-confirmatory for humans.
4	Neuroinflammation	Inflammatory signaling ↓	Reduced glial inflammatory stress	Recent AD-like mouse work supports reduced neuroinflammation. This is likely secondary to redox and amyloid-related effects rather than a uniquely direct anti-inflammatory drug action.
5	Mitochondrial dysfunction	Mitochondrial injury ↓	Improved neuronal survival	Animal AD-model data support reduced oxidative mitochondrial injury and improved cognitive outcomes, but human confirmation is limited.
6	Cognitive performance	Cognition ↑ (association-dependent)	Functional outcome support	Observational studies and some long-term supplementation data suggest slower cognitive decline or better performance, but shorter-term standalone intervention effects are inconsistent.
7	Clinical Translation Constraint	Evidence strength ↔ / limited	Weak translation to therapy	AD-specific human evidence is mostly associative; β-carotene itself is not an approved AD treatment, and its benefits may reflect broader dietary patterns rather than isolated supplement efficacy.

ROS, Reactive Oxygen Species: Click to Expand ⟱

Source: HalifaxProj (inhibit)

Type:

Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination


Item  ROS↑  NRF2  Condition  Mechanism Class  Remarks  

ROS">Piperlongumine
+++  ↓  [D][T]  ROS-dominant
Selective <span class="wphighlight">ROS</span> stressor, Prevents compensatory upregulation of NRF2, ie GSH↓



ROS">Shikonin
+++ ↓/± [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + glycolysis + GPX4 inhibition



ROS">Vitamin K3 (menadione)
+++ ↓ [D] ROS-dominant
Quinone redox cycler; toxicity limits use



ROS">Copper (ionic / nano)
+++ ↓ [Fe][F] ROS-dominant
Fenton-type redox chemistry



ROS">Sodium Selenite
+++ ↓ [D] ROS-dominant
Pro-oxidant, depletes GSH



ROS">Juglone
+++ ↓ [D] ROS-dominant
Strong quinone <span class="wphighlight">ROS</span> chemistry



ROS">Auranofin
+++ ↓ [D] ROS-dominant
TrxR inhibition → redox collapse



ROS">Photodynamic Therapy (PDT)
+++ 0 [L][O₂] ROS-dominant
Singlet oxygen is core cytotoxic mechanism



ROS">Radiotherapy / Radiation
+++ 0 [O₂] ROS-dominant
DNA damage largely via <span class="wphighlight">ROS</span>



ROS">Doxorubicin
+++ ↓ [D] ROS-dominant
Chemo; redox cycling + mitochondrial <span class="wphighlight">ROS</span>



ROS">Cisplatin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> contributes to DNA/protein damage



ROS">Salinomycin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated CSC toxicity



ROS">Artemisinin / DHA
++ ↓ [Fe][T] ROS-dominant
Iron-activated radical generation



ROS">Sulfasalazine
++ ↓ [C][T] ROS-dominant
Ferroptosis; xCT inhibition → lipid <span class="wphighlight">ROS</span>



ROS">FMD / fasting
++ ↓ [M][C][O₂] ROS-dominant
Metabolic stress → mitochondrial <span class="wphighlight">ROS</span>



ROS">Vitamin C (pharmacologic)
++ ↓ [Fe][D] ROS-dominant
Extracellular H₂O₂ at high dose



ROS">Silver nanoparticles
++ ± [F][D] ROS-dominant
<span class="wphighlight">ROS</span> common; selectivity unreliable



ROS">Gambogic acid
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Parthenolide
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + NF-κB suppression



ROS">Plumbagin
++ ↓ [D] ROS-dominant
Quinone <span class="wphighlight">ROS</span> driver



ROS">Allicin
++ ↓ [D] ROS-dominant
Thiol-reactive oxidative stress



ROS">Ashwagandha (Withaferin A)
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Berberine
++ ↓ [D][M] ROS-dominant
Mitochondrial <span class="wphighlight">ROS</span> induction



ROS">PEITC
++ ↓ [D][C] ROS-dominant
GSH depletion + <span class="wphighlight">ROS</span>



ROS">Methionine restriction
+ ↓ [M][C][T] ROS-secondary
Redox vulnerability increased; <span class="wphighlight">ROS</span> indirect



ROS">DCA
+ ± [M][T] ROS-secondary
<span class="wphighlight">ROS</span> via forced OXPHOS



ROS">Capsaicin
+ ± [D][T] ROS-secondary
Ca²⁺ stress → <span class="wphighlight">ROS</span>



ROS">Galloflavin
+ 0 [D] ROS-secondary
<span class="wphighlight">ROS</span> not primary driver



ROS">Piperine
+ ± [D][F] ROS-secondary
Weak <span class="wphighlight">ROS</span> induction



ROS">Propyl gallate
+ ↓ [D] ROS-secondary
Pro-oxidant at high dose



ROS">Scoulerine
+ ? [D][T] ROS-secondary
Sparse <span class="wphighlight">ROS</span> data



ROS">Thymoquinone
± ± [D][T] Dual redox
Antioxidant ↔ pro-oxidant switch



ROS">Emodin
± ± [D][T] Dual redox
Not cancer-exclusive



ROS">Alpha-lipoic acid (ALA)
± ↑ [D][M] NRF2-dominant
Antioxidant at low dose



ROS">Curcumin
± ↑/↓ [D][F] NRF2-dominant
Hormetic redox behavior



ROS">EGCG
± ↑/↓ [D][O₂] NRF2-dominant
Auto-oxidation artifacts common



ROS">Quercetin
± ↑/↓ [D][Fe] NRF2-dominant
GSH-dependent cycling



ROS">Resveratrol
± ↑ [D][M] NRF2-dominant
<span class="wphighlight">ROS</span> only at high dose



ROS">Sulforaphane
± ↑↑ [D] NRF2-dominant
Strong NRF2 activator



ROS">Lycopene
0 ↑ — Antioxidant
Consistently antioxidant



ROS">Rosmarinic acid
0 ↑ — Antioxidant
Primarily antioxidant



ROS">Citrate
0 0 — Neutral
Metabolic; not a <span class="wphighlight">ROS</span> agent

Scientific Papers found: Click to Expand⟱

5561-

betaCar,

Carotenoid Supplementation for Alleviating the Symptoms of Alzheimer’s Disease

Review,

AD,

*ROS↓, *cognitive↑, *BBB↑, *lipid-P↓, *eff↑,

1566-

betaCar,

Lyco,

Antioxidant and pro-oxidant effects of lycopene in comparison with beta-carotene on oxidant-induced damage in Hs68 cells

in-vitro,

Nor,

HS68

*ROS↑, *ROS⇅, *Dose?,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

Total Targets: 0

Pathway results for Effect on Normal Cells:

Functional Outcomes ⓘ

cognitive↑, 1,
Total Targets: 8

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:194  Target#:275  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

beta-carotene(VitA) / ROS Cancer Research Results

Cancer Mechanistic relevance table

Alzheimer's disease relevance table

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Barriers & Transport ⓘ

Drug Metabolism & Resistance ⓘ

Functional Outcomes ⓘ

Home Page